Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Organogenesis Holdings
ORGO
Organogenesis Holdings
Aggressive Discounting Will Squeeze Margins While Aging Population Buoys Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
23 Aug 25
Updated
23 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$7.00
30.1% undervalued
intrinsic discount
23 Aug
US$4.89
Loading
1Y
66.9%
7D
3.4%
Author's Valuation
US$7.0
30.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$7.0
30.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-60m
632m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$631.6m
Earnings US$60.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
17.99%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$60.84m
Earnings '28
x
15.55x
PE Ratio '28
=
US$945.89m
Market Cap '28
US$945.89m
Market Cap '28
/
111.14m
No. shares '28
=
US$8.51
Share Price '28
US$8.51
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$6.99
Fair Value '25
